Please wait a minute...
Reviews in Cardiovascular Medicine  2021, Vol. 22 Issue (3): 799-805     DOI: 10.31083/j.rcm2203086
Special Issue: Risk Factors for Cardiovascular Diseases
Review Previous articles | Next articles
The blooming intersection of subfatin and metabolic syndrome
Shenglei Huang1, 2, †, Lei Cao3, †, Hongwei Cheng4, *(), Dongliang Li1, 2, Yi Li5, Zhixian Wu1, 2, *()
1Department of Hepatobiliary Disease, Fuzhou General Hospital (Dongfang Hospital), Xiamen University, 350025 Fuzhou, Fujian, China
2Department of Hepatobiliary Disease, The 900th Hospital of Joint Logistics Support Force, 350025 Fuzhou, Fujian, China
3Department of Pathology, Quanzhou Women's and Children's Hospital, 362000 Quanzhou, Fujian, China
4School of Public Health, Xiamen University, 361002 Xiamen, Fujian, China
5Department of Oncology, 920th Hospital of Joint Logistics Support Force, 650032 Kunming, Yunnan, China
Download:  PDF(370KB)  ( 556 ) Full text   ( 17 )
Export:  BibTeX | EndNote (RIS)      
Abstract:
Metabolic Syndrome (MS) remains the leading cause of mortality and morbidity globally. Adipose tissue releases adipokines that play key roles in metabolic and cardio-cerebro-vascular homeostasis. Subfatin, induced after exercise or upon cold exposure in adipose tissue, is a novel secreted protein homologous to Metrn, a neutrophic factor with angiogenic properties. The protein was proved to be of great significance in the browning of white adipose tissue (BWT) and insulin resistance (IR). It affected insulin sensitivity at least via its local autocrine/paracrine action through AMP-activated protein kinase (AMPK) or peroxisome proliferator-activated receptor δ (PPAR-δ) dependent signaling. Subfatin blocked the release of inflammatory mediators, improved intracellular insulin signal transduction and reversed IR. It also improved glucose tolerance and played a key role in metabolism and cardiovascular and cerebrovascular homeostasis. It was reported that the level of serum subfatin was significantly correlated with the occurrence and severity of coronary heart disease, which might be a new target for the treatment of coronary heart disease. In addition, exercise increased the level of subfatin in circulation and adipose tissue, promoted energy consumption, improved glucose and lipid metabolism, increased the heat production of brown fat, and strengthened the anti-inflammatory mechanism. Given its role in metabolic disorders, subfatin is considered as a candidate biomarker of MS. However, the clinical significance of subfatin remains largely unclear. The purpose of this article is to review the research on the effect of subfatin on MS in recent years.
Key words:  Subfatin      Metrnl      Cometin      Interleukin 39      Metabolic syndrome     
Submitted:  10 June 2021      Revised:  23 July 2021      Accepted:  13 August 2021      Published:  24 September 2021     
Fund: 
2020J011131/General Project of Fujian Natural Science Foundation
2019Y9044/Science and Technology Innovation Joint Fund Project of Fujian Province
2018Q07/Outstanding Youth funds of the 900th Hospital of Joint Logistic Support Force, PLA
*Corresponding Author(s):  zxwu@xmu.edu.cn (Zhixian Wu); hongwei1026@hotmail.com (Hongwei Cheng)   
About author:  These authors contributed equally.

Cite this article: 

Shenglei Huang, Lei Cao, Hongwei Cheng, Dongliang Li, Yi Li, Zhixian Wu. The blooming intersection of subfatin and metabolic syndrome. Reviews in Cardiovascular Medicine, 2021, 22(3): 799-805.

URL: 

https://rcm.imrpress.com/EN/10.31083/j.rcm2203086     OR     https://rcm.imrpress.com/EN/Y2021/V22/I3/799

[1] Helmi Ben Saad. Comments on "Cardiovascular effects of waterpipe smoking: a systematic review and meta-analysis"[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 267-268.
[2] Norman E. Lepor, Dean D. Fouchia, Peter A. McCulloughsup. New Vistas for the Treatment of Obesity: Turning the Tide Against the Leading Cause of Morbidity and Cardiovascular Mortality in the Developed World[J]. Reviews in Cardiovascular Medicine, 2014, 15(S2): 1-21.
[3] Arthur R. Menezes, Carl J. Lavie, James J. DiNicolantonio, James O'Keefe, Daniel P. Morin, Sammy Khatib, Franz H. Messerli, Richard V. Milani. Cardiometabolic Risk Factors and Atrial Fibrillation[J]. Reviews in Cardiovascular Medicine, 2013, 14(2-4): 73-81.
[4] Norman E. Leporn, Dean D. Fouchian, Peter A. McCulloughn. New Vistas for the Treatment of Obesity: Turning the Tide Against the Leading Cause of Morbidity and Cardiovascular Mortality in the Developed World[J]. Reviews in Cardiovascular Medicine, 2013, 14(1): 20-40.
[5] Sanjay Mehra, Hossein Movahed, Assad Movahed. Coronary Artery Calcium Scoring[J]. Reviews in Cardiovascular Medicine, 2011, 12(2): 94-103.
[6] Adam Whaley-Connell, Peter A. McCullough, James R. Sowers. The Role of Oxidative Stress in the Metabolic Syndrome[J]. Reviews in Cardiovascular Medicine, 2011, 12(1): 21-29.
[7] Benjamin L. Rosin. The Progression of Cardiometabolic Risk to Cardiovascular Disease[J]. Reviews in Cardiovascular Medicine, 2007, 8(S4): 3-8.
[8] Anne L. Peters. Identification of Appropriate Patients for Cardiometabolic Risk Management[J]. Reviews in Cardiovascular Medicine, 2007, 8(S4): 9-16.
[9] Steven M. Haffner. Unmet Needs in Controlling Metabolic Disease[J]. Reviews in Cardiovascular Medicine, 2007, 8(S4): 17-24.
[10] Karol E. Watson. Novel Therapies for Cardiometabolic Risk Reduction and Implications for Clinical Practice[J]. Reviews in Cardiovascular Medicine, 2007, 8(S4): 37-42.
[11] Lawrence A. Leiter. From Hyperglycemia to the Risk of Cardiovascular Disease[J]. Reviews in Cardiovascular Medicine, 2006, 7(S2): 3-9.
[12] Stuart W. Zarich. Cardiovascular Risk Factors in the Metabolic Syndrome: Impact of Insulin Resistance on Lipids, Hypertension, and the Development of Diabetes and Cardiac Events[J]. Reviews in Cardiovascular Medicine, 2005, 6(4): 194-205.
[13] Keith C. Ferdinand, Keith C. Ferdinand. The Epidemic of Diabetes Mellitus and the Metabolic Syndrome in African Americans[J]. Reviews in Cardiovascular Medicine, 2004, 5(S3): 28-33.
[14] Karol E. Watson, Barbara N. Horowitz, Gary Matson. Lipid Abnormalities in Insulin Resistant States[J]. Reviews in Cardiovascular Medicine, 2003, 4(4): 228-236.
No Suggested Reading articles found!